When our publisher, Steve Freed, first got me involved in diabetes, I was not aware of any pharmacists actually taking care of patients. One of the first pharmacists that he mentioned to me and introduced me to was Dr. Keith Campbell. Keith was a CDE and professor of pharmacy at …

Today, my patient, a woman, 42 years of age, brought her daughter who is 18 years of age with her for her visit. Mother has PCOS, class III obesity and type 2 diabetes. She told me she brought her because of the strong family history of diabetes on both sides of his family. She wanted her to understand what someone who has diabetes goes through.

In part 2 of this Exclusive Interview, Dr. Aaron Vinik talks with Diabetes in Control Publisher Steve Freed during the AACE 2017 convention in Austin, Texas about the work and results of the EMPA-REG and LIRA studies, among others, and the medication that truly is the game changer in the world of diabetes treatment.

In this week's Homerun Slides, we start taking a look at the latest technology and medications to impact diabetes management.

NAFLD is defined as steatosis (greater than 5–10% of hepatocytes are fatty), which is not due to excess use of alcohol (defined in European and American guidelines as greater than 20 g of alcohol daily for women and greater than 30 g for men), or other conditions as determined by careful family and medical history, and laboratory tests to exclude at least steatosis due to viral and autoimmune causes and iron overload.